Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

LVADs as destination therapy

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Key clinical point: Landmark trial paves way to much wider use of LVADs as destination therapy.

Major finding: The 2-year rate of survival free of disabling stroke or reoperation to replace or remove a malfunctioning LVAD was 79.5% with the novel HeartMate 3 LVAD, compared with 60.2% with the commonly used HeartMate II axial-flow device.

Study details: This was a randomized, unblinded, multicenter study of more than 1,000 patients with advanced heart failure.

Disclosures: The MOMENTUM 3 trial was funded by Abbott. The presenter reported receiving research grants from and serving as a consultant to the company.

Source: Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

Read the article.

Citation:

Mehra MR et al. New Engl J Med DOI: 10.1056/NEJMoa1800866.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in Thrombosis

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia

VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251